Century Therapeutics Inc

NASDAQ IPSC

Data sourced from

and

Download Data

Century Therapeutics Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2024: 134.12

Century Therapeutics Inc Working Capital To Sales Ratio is 134.12 for the Trailing 12 Months (TTM) ending March 31, 2024, a -51.19% change year over year. The working capital to sales ratio measures the proportion of working capital to revenue. It is calculated by dividing the difference between current assets and current liabilities by revenue. This ratio provides insights into the efficiency of working capital utilization relative to revenue generation. A higher ratio suggests better utilization of working capital to generate sales revenue.

Century Therapeutics Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 274.78, a -15.31% change year over year.
Century Therapeutics Inc Working Capital To Sales Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 324.47.

NASDAQ: IPSC

Century Therapeutics Inc

CEO	Dr. Osvaldo Flores Ph.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street, Philadelphia, PA, United States, 19104
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends